Carlos III Health Institute confirms antibodies in vaccinated patients
According to the institute, both Pfizer and AstraZeneca vaccines work best.

The Carlos III Health Institute, a government institute in Spain, says people treated with the first dose of the drug from AstraZeneca plc (NASDAQ: AZN) and the second dose from Pfizer Inc (NYSE: PFE) had improved safety and showed effectiveness against COVID-19. According to the results of the Combivacs study conducted by the Carlos III Health Institute, people who received the first dose of the AstraZeneca vaccine and then the Pfizer drug had 30 to 40% higher levels of IgG antibodies in their blood. This is a significant achievement compared to people who received two doses of the AstraZeneca vaccine. Individuals who received the Pfizer drug as a second dose had a significant increase in neutralizing bodies than those who received the AstraZeneca vaccine as a second dose. The clinical trial enrolled 670 people between the ages of 18 and 59 who were given the first dose of the AstraZeneca vaccine. It administered Pfizer's drug to 450 people in the clinical trial. The institute observed side effects such as general malaise, headache and muscle pain in only 1.8% of the participants. However, according to Dr. Magdalena Campins not serious. In a study in the UK of a mix of AstraZeneca and Pfizer vaccines (first dose AstraZeneca vaccine and second dose Pfizer product or vice versa), symptoms such as chills or headache were moderate or mild when compared to two doses of the same type of vaccine. An evaluation of the immune reactions is expected shortly. Spain has entrusted the clinical trial to the Carlos III Health Institute to see what to do after restricting the dose of AstraZeneca to people over 60 because of concerns about blood clots in younger people. According to widespread reports of blood clots, younger people who received the first dose of the AstraZeneca vaccine are excluded from the second dose of the AstraZeneca vaccine. BioNTech SE and Pfizer signed an agreement with the European Commission (EC) on May 20, 2021. Under the terms of the contract, both companies will deliver 900 million COMIRNATY cans to the EU. The EU has an option to request an additional 900 million cans from these companies. The new agreement adds to the previous commitment of 600 million cans to the EU in 2021.





